By Fernando Caudevilla (DoctorX)
Access to cannabinoid treatments generates great hope among patients suffering from chronic or painful conditions. This human need is understandable and legitimate. However, communicating scientific progress requires rigorous precision to avoid creating false expectations or diverting resources from validated therapies. In this article, we critically analyze how information about medicinal cannabis is presented in various spheres: from certain specialized media outlets to user associations and industry companies.
In brief
- Crucial difference: A study in mice or cells does not guarantee efficacy in humans. Human biological complexity is incomparably greater.
- Risk of self-promotion: The indiscriminate use of the term “therapeutic” by associations without medical supervision can endanger vulnerable patients.
- Product quality: The lack of clear legislation makes it difficult to guarantee standardized therapeutic concentrations in homegrown or unregulated products.
- Communication strategy: Separating the defense of civil rights (cultivation, possession) from medical claims is fundamental for real scientific progress.
The problem of scientific extrapolation
It is common to find sensationalist headlines promising miracle cures based on preliminary research. A recurring example is the use of cannabis against cancer. Although there are fascinating studies, such as those conducted with murine models or specific cell lines (for example, tumors expressing the ErbB2 gene), these results should not be interpreted as an immediate clinical indication.
In-vitro and in-vivo animal trials constitute the first step of pharmacological research. Their objective is to identify biological mechanisms, potential toxicity, or preliminary efficacy. However, these findings are insufficient to authorize a treatment in humans. Human physiology possesses an infinite complexity superior to that of any animal model; what works in a mouse may have no effect at all, or even be counterproductive, in a human patient.
Medical science requires years, decades, and millions in investment to move a finding from the laboratory to the hospital. Currently, there is no solid evidence supporting the use of cannabinoids as a primary treatment for malignant tumors in people. Stating otherwise without nuance is irresponsible and may lead patients to abandon conventional oncological therapies with proven efficacy.
The role of activism and self-promotion
There is a diversity of interests within the so-called “cannabis movement,” ranging from militant activism to commercial interests. Often, these entities call themselves “therapeutic” or promote specific varieties for medicinal purposes without the supervision of specialized physicians.
This situation poses significant risks. An association that offers advice on cannabis must have qualified healthcare professionals capable of evaluating each case individually, just as any other medical specialist would. The proliferation of clubs and associations that lack this professional backing can result in inadequate advice for patients with serious pathologies.
Furthermore, the marketing of products labeled as “therapeutic” without strict quality controls is a serious problem. Cannabinoid concentrations depend not only on the genetics of the seed but also on cultivation, curing, and processing. Without clear legislation requiring certified analysis, any product can be advertised with false medical claims, making it difficult for the user to make informed decisions.
Harm reduction: reading information critically
Faced with the abundance of news about “cures” or miraculous properties, it is essential to apply a critical filter. Regarding any extraordinary claim:
- Verify the study model: Is it cells in culture, mice, or humans?
- Consult the original publication: Headlines often omit important nuances present in full scientific articles.
- Evaluate the source: Is it a peer-reviewed scientific medium or a news portal without methodological rigor?
The maximum expression of risk is observed when home remedies are promoted to treat advanced cancers, such as cannabis oil in non-standardized doses. Although the plant has recognized analgesic and anti-nausea properties, its use as a substitute for oncological treatments without medical supervision is dangerous.
Separating civil rights from medical claims
It is fundamental to distinguish between civil claims (the right to cultivate, possess, or consume cannabis in the private sphere) and medical claims. Adult citizens should have rights regarding their bodily privacy and possession without fear of arbitrary reprisals. These are ethical, political, and sociological issues that can be debated independently of the therapeutic efficacy of the compound.
Defending civil rights does not necessarily imply validating all medical claims. Likewise, recognizing the pharmacological potential of cannabinoids does not justify ignoring the risks or exaggerating their benefits without evidence. Science must advance on its own terrain, free from ideological or commercial pressures that could distort reality.
Towards responsible regulation
The future regulation of medicinal cannabis should prioritize legal certainty and access to standardized products. This includes:
- Mandatory quality analysis to ensure therapeutic concentrations.
- Strict medical supervision in all cannabinoid treatments.
- Public education on the difference between recreational, medicinal, and experimental use.
In the meantime, patients must be well-informed before considering any therapeutic change. Hope is a powerful engine, but it must be guided by rigorous scientific evidence so as not to become a trap that exposes vulnerable people to unnecessary risks.
At Psiconáutica.org, we will continue to analyze specific pathologies where cannabis or its derivatives have demonstrated real clinical efficacy, always under an approach of harm reduction and scientific prudence. Critical awareness is our best tool for navigating this complex and promising field.
